Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers is a phase 2, randomised interventional study registered as NCT05846789 by Kathy Miller, with a registry enrolment figure of 168 participants, started 2024-07-02 and due to reach its primary completion in 2027-12. Interventions recorded: SOC Chemotherapy; Tocilizumab/Tocilizumab Biosimilar. Conditions listed: Metastatic Breast Cancer; Triple Negative Breast Cancer; Estrogen-receptor-low Breast Cancer; ER Positive, HER2 Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-positive (ER and PR ≤ 1% weak staining)". Sites: United States. No results are recorded here; the registry entry is the source.